Cargando…

Anti–factor Xa activity assays of direct‐acting oral anticoagulants during clinical care: An observational study

BACKGROUND: Direct‐acting oral anticoagulants (DOACs) are increasingly used to prevent and treat thromboembolism. Although measurement of DOAC concentrations is not currently recommended as part of routine patient care, measurement of DOAC concentrations with anti–factor Xa activity assays have rece...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sukumar, Smrithi, Cabero, Melissa, Tiu, Sharon, Fang, Margaret C., Kogan, Scott C., Schwartz, Janice B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114026/ https://www.ncbi.nlm.nih.gov/pubmed/34013157 http://dx.doi.org/10.1002/rth2.12528

Ejemplares similares

Comparison of three different anti-Xa assays in major orthopedic surgery patients treated with direct oral anticoagulant
por: Ikejiri, Makoto, et al.
Publicado: (2017)

Effect of dexamethasone on direct Xa-inhibitor oral anticoagulant plasma levels in patients with COVID-19
por: Bosch, Floris T.M., et al.
Publicado: (2021)

Direct oral anticoagulants‐Remove versus Taipan snake venom time for detection of a lupus anticoagulant in patients taking oral direct factor Xa inhibitors
por: White, Danielle, et al.
Publicado: (2022)

Direct-acting Oral Anticoagulants: An Overview
por: Salem, Hatem H.
Publicado: (2017)

Medications that interact with direct-acting oral anticoagulant exposure
por: de Vries, T. A. C., et al.
Publicado: (2021)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Impact of different dose reduction criteria for anti‐Xa direct oral anticoagulants on bleeding complications: A single center observational study
por: Fukaya, Hidehira, et al.
Publicado: (2022)

Trends in direct oral anticoagulant use in patients presenting with acute stroke
por: Teow, Kang H., et al.
Publicado: (2022)

Direct-Acting Oral Anticoagulants and Their Reversal Agents—An Update
por: Kustos, Stephanie A., et al.
Publicado: (2019)

The Tick-Derived Anticoagulant Madanin Is Processed by Thrombin and Factor Xa
por: Figueiredo, Ana C., et al.
Publicado: (2013)

Major bleeding during oral anticoagulant therapy associated with factor V activation by factor Xa
por: Maag, Anja, et al.
Publicado: (2021)

Direct oral anticoagulant use and risk of severe COVID‐19
por: Flam, B., et al.
Publicado: (2020)

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data
por: Kee, Youn Kyung, et al.
Publicado: (2023)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Andexanet alfa for reversal of factor Xa inhibitor-associated anticoagulation
por: Carpenter, Elise, et al.
Publicado: (2019)

An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
por: Cini, Michela, et al.
Publicado: (2019)

Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
por: Bounameaux, Henri, et al.
Publicado: (2014)

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
por: Gao, Lulu, et al.
Publicado: (2017)

Direct-Acting Oral Anticoagulants as Prophylaxis Against Thromboembolism in the Nephrotic Syndrome
por: Sexton, Donal J., et al.
Publicado: (2018)

Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians
por: Peacock, W. Frank, et al.
Publicado: (2016)

Adding Herbal Products to Direct-Acting Oral Anticoagulants Can Be Fatal
por: Maadarani, Ossama, et al.
Publicado: (2019)

Efficacy and Safety of Direct-Acting Oral Anticoagulants (DOACs) in the Overweight and Obese
por: Doucette, Kimberley, et al.
Publicado: (2020)

The use of direct acting oral anticoagulants in patients with COVID-19 infection
por: Aly, Ragia, et al.
Publicado: (2021)

Direct-Acting Oral Anticoagulant Therapy in Cancer Patients—A Review
por: Górnicki, Tomasz, et al.
Publicado: (2023)

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors
por: Verhoef, Daniël, et al.
Publicado: (2017)

Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists
por: Fedorov, Kateryna, et al.
Publicado: (2021)

Rivaroxaban, a Direct Oral Factor Xa Inhibitor, Attenuates Atherosclerosis by Alleviating Factor Xa–PAR2-Mediated Autophagy Suppression
por: Ito, Yusuke, et al.
Publicado: (2021)

Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Direct oral Xa inhibitors for the treatment of venous thromboembolism after bariatric surgery
por: Kushnir, Margarita, et al.
Publicado: (2022)

Guideline-discordant dosing of direct-acting oral anticoagulants in the veterans health administration
por: Rose, Adam J., et al.
Publicado: (2021)

Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!
por: Abdelnabi, Mahmoud, et al.
Publicado: (2022)

Edoxaban, a Factor Xa-Specific Direct Oral Anticoagulant, Significantly Suppresses Tumor Growth in Colorectal Cancer Colon26-Inoculated BALB/c Mice
por: Hiramoto, Keiichi, et al.
Publicado: (2023)

Bedside anti-Xa measurement for therapeutic assessment of a prophylactic anticoagulation regimen
por: Dewulf, B, et al.
Publicado: (2013)

The Role of Factor Xa-Independent Pathway and Anticoagulant Therapies in Cancer-Related Stroke
por: Kim, Hyung Jun, et al.
Publicado: (2021)

Structure‐function of anticoagulant TIX‐5, the inhibitor of factor Xa‐mediated FV activation
por: Maag, Anja, et al.
Publicado: (2021)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson, Pontus B
Publicado: (2015)

Measuring residual anti‐Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa
por: Bourdin, Matthieu, et al.
Publicado: (2021)

To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice
por: Ahuja, Tania, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_j6fs76c9q7qlhs6s5q1gfif99r